6:00 PM
 | 
Sep 27, 2013
 |  BC Extra  |  Top Story

First approval for simeprevir

Medivir AB (SSE:MVIR B) was up SEK11.50 (11%) to SEK112 on Friday after it and partner Johnson & Johnson (NYSE:JNJ) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Sovriad simeprevir to treat HCV...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >